Ubicom Holdings. Inc. · TSE:3937
Ubicom — Q3 FY2025 Earnings Presentation
36 slides from Ubicom's earnings presentation, Feb 5, 2026
Slide 1: FY2025 Q3 Financial Results Materials
Ubicom Holdings, Inc. (Standard Market of TSE: 3937) FY2025 Q3 Financial Results Materials February. 5, 2026
Slide 2: Table of Contents
Table of Contents 01 Highlights of Consolidated Financial Results for FY2025 Q3 P.4 02 Overview of Consolidated Financial Results (P/L) for FY2025 Q3 P.5 03 Medical Business P.6 04 Technology Consulting Business P.12 05 Dividend Policy P.20 06 Business Forecast ＆ Performance Trends P.22 07 Appendix
Slide 3: Both businesses have pivoted toward strategic investments in key competitive domains
Both businesses have pivoted toward strategic investments in their key competitive domains Technology Consulting Business From Q3, we have fully shifted its focus toward the AI-driven development domain. ～Transforming the business model into a high-value-added, high-margin AI solutions company～ Ubic
Slide 4: Highlights of Consolidated Financial Results for FY2025 Q3
Highlights of Consolidated Financial Results for FY2025 Q3 In the Q3, we prioritized structural transformation aimed at sustainable operating profit growth from the next fiscal year onward, rather than short-term profit maximization. As a result, on a consolidated basis, revenue and profits declined
Slide 5: Overview of Consolidated Financial Results (P/L) for FY2025 Q3
Overview of Consolidated Financial Results (P/L) for FY2025 Q3 • Sales, operating income, and ordinary income all declined YoY, while sales increased YoY. • In the technology consulting business, we prioritized a shift to an AI-driven development model leveraging platforms such as IBM’s watsonx and
Slide 6: Medical Business
Medical Business 6
Slide 7: Medical Business: Segment Performance Overview for FY2025 Q3
Medical Business： Segment Performance Overview for FY2025 Q3 ・Both sales revenue and operating profit reached record highs, reflecting continued growth driven by steady accumulation. ・Revenue and profit growth was achieved while absorbing temporary expenses such as integration costs (PMI costs) asso
Slide 8: User's Trend of the Core Solution Mighty Series
AI×Subscription Model User’s Trend of the Core Solution「Mighty」Series The implementation of workstyle reforms for medical doctors in April 2024 has led to an acceleration of digital transformation in the medical industry. While focusing on converting existing users, the number of users is steadily i
Slide 9: Long-Term Strategy: M&A Strategy (Nationwide Sales Distributor M&A)
Long-Term Strategy: M&A Strategy (Nationwide Sales Distributor M&A) To maximize profitability in medical business between 2025 and 2030, We will promote a shift to a direct sales model through group-wide M&A initiatives. Progress as of Q3: Completion of ISM Group‘s integration. Discussions are progr
Slide 10: Strengthening the Revenue Structure through M&A of Sales Agencies
Strengthening the Revenue Structure through M&A of Sales Agencies By acquiring sales distributors through M&A, we are shifting from a distributor-based model to a direct sales model within the Group, thereby enhancing our revenue structure. Grouping with AIS Medical Institution Distributor Medical I
Slide 11: Scenario for Mid-to-Long-Term Growth in the Medical Business
Scenario for Mid-to-Long-Term Growth in the Medical Business To achieve mid-to-long-term growth, we will combine the organic growth of stable stock-type businesses with the Non-linear growth through M&A strategies. Business Growth Strategy Image M&A Target: 8 to 10 companies by 2025 and 2030 Creatio
Slide 12: Technology Consulting Business
Technology Consulting Business 12
Slide 13: Technology Consulting Business: Overview by Segment for Q3 of FY2025
Technology Consulting Business： Overview by Segment for Q3 of FY2025 (Business Performance) From Q3, we began training approximately 50 AI engineers to leverage watsonx and related technologies. As part of our preparations for full-scale acceptance of AI-driven projects, we strategically restrained
Slide 14: Technology Consulting Business: Philippine Subsidiary Performing Strongly
Technology Consulting Business: Philippine Subsidiary Performing Strongly 【Factors behind strong performance at the Philippine subsidiary (Lower sales, higher income) • Revenue of the Philippines subsidiary is strong across projects routed through the Japanese parent company and direct or overseas c
Slide 15: Building an AI-Driven Development Framework Leveraging watsonx
Building an AI-Driven Development Framework Leveraging watsonx (Mid-to-Long-Term Strategy) As a core partner of IBM Japan, we are leveraging the enterprise business AI platform ※ “watsonx” and related technologies to build an AI Center at our Philippines base. This initiative represents a strategic
Slide 16: Roadmap for Building an AI-Driven Development Framework
Roadmap for Building an AI-Driven Development Framework Leveraging IBM’s “watsonx” and related technologies Phased development of an AI-Driven delivery model using IBM’s “watsonx” Future Implementation & and related technologies Commercialization Phase Validation ⇒ PoC ⇒ Implementation Full-scale or
Slide 17: Key Drivers for Improving Efficiency in the AI-Driven Development: Personnel Strategy
Key Drivers for Improving Efficiency in the AI-Driven Development ① Personnel Strategy ② Productivity Improvement Converting existing resources Development Expansion of high-value-added into AI-capable personnel efficiency High-productivity watsonx +38％※ High-margin 人材戦略 projects ① Personnel Strateg
Slide 18: Key Drivers for Improving Efficiency: Productivity Improvement
Key Drivers for Improving Efficiency in the AI-Driven Development ② Productivity Improvement We drive efficiency in design, implementation, testing, and other development processes through an AI-driven development framework. In the targeted development processes, we are validating the potential to a
Slide 19: Target Domains for Building an AI-Driven Development Framework
Target Domains for Building an AI-Driven Development Framework Leveraging watsonx and related technologies The generative AI market is expected to expand both in Japan and globally, with substantial demand projected toward 2030, particularly in the finance, manufacturing, and energy sectors. In ligh
Slide 20: Dividend Policy
Dividend Policy 20
Slide 21: Dividend Policies to Enable Shareholders to Share in the Benefits of Growth
Dividend Policies to Enable Shareholders to Share in the Benefits from the Growth of Our Company 【Dividend Policies】 ① While concerns over U.S. tariffs had been raised, their actual impact is currently expected to be more limited than initially anticipated. In light of the steady performance of our
Slide 22: Business Forecast & Performance Trends
Business Forecast ＆ Performance Trends 22
Slide 23: Business Forecast and Performance Trends
Business Forecast and Performance Trends Feb, 2026 Change in market segment to “TSE Standard Market” Advancing M&A strategy within the Medical Business and Concentrating investment towards establishing an AI-driven utilization framework leveraging IBM's “watsonx” and related technologies within the
Slide 24: Appendix
Appendix 24
Slide 25: Our Business Model: A Model for Resolving Social Issues in Japan
Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 Technology Consulting Business Reforming the workstyle of Against the backdrop of an ※ medical professionals anticipated shortage of 3.26 Improving the profitability Mission
Slide 26: The Tailwind created by Social issues and Political measures
The Tailwind created by Social issues and Political measures (Market environment) Increasing deficits of medical institutions and social security spending cuts: three growth opportunities arising from structural challenges Increasing deficits in The coverage rate of EMR is Business fields aligned wi
Slide 27: The flagship product of the Mighty series
The flagship product of the “Mighty” series, which leverages AI to enhance operational efficiency in healthcare institutions 【For doctors】AI-oriented EMR Diagnosis Input Support & Input Verification System for Doctors By linking with electronic medical records, the AI derives possible diagnoses ba
Slide 28: Impact of M&A Strategy Execution (KPI Changes)
Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the group's direct sales ratio. ＜Factors contributing to LTV ※1 improvement＞ Content Measurement details Increase of ①Inclusion of agency profits in grou
Slide 29: Medical Business: Revenue Recognition Methods (Billing Methods)
Medical Bussiness：Revenue Recognition Methods (Billing Methods) License revenue for the Mighty series adopts a “instalment recognition” method. With the increase in contract numbers, sales steadily accumulate on a monthly basis, achieving revenue stabilization. Furthermore, the AI × subscription mod
Slide 30: Technology Consulting Business: About AI-driven development model
Technology Consulting Business： About AI-driven development model 【Background for Adopting watsonx in AI-Driven Development Model】 Dramatic Growth Potential • AI-powered models enable the automation of development processes, significantly reducing development time. • As a result, scalable growth tha
Slide 31: A new value and differentiation strategy created by Designed Lab-type Development
A new value and differentiation strategy created by the「Designed Lab-type Development」 【 Risks and Concerns of Conventional Offshore Development 】 In case the of setting up an offshore base In case the of conventional Lab-type development Client Offshore development company Client’s base Client Lab
Slide 32: Promotion of Group Businesses Based on Social Significance
Promotion of Group Businesses Based on Social Significance Considering business and capital alliances with leading global companies for the second growth phase Provision of solutions that are beneficial to three key areas: pressing need for workstyles Growing demand due to the reforms for medical do
Slide 33: ESG: For sustainable growth of business, society, and client companies
ESG：For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed E ・To reduce CO2 emissions at the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili
Slide 34: Corporate Profile
Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Standard Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, etc. ■Business description: Technology Consulting Business In order to solve the problem of shortage of IT engineers
Slide 35: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time. Such forward-looking statements are subject to various risks and uncertaintie
Slide 36: Holdings, Inc.
Holdings, Inc. = fe) Q Q =) 36